HA TECH is an Australian based Biotechnology company developing & delivering effective Diagnostic, Pharmaceutical products an ... d innovative technologies to reduce burden of disease. Our focus is on the diagnosis of serious infectious diseases: respiratory, including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. We are dedicated to long-term investments to develop pharmaceutical products and Active Ingredients to treat the largest chronic healthcare burdens such as cardiovascular disease and diabetes. The Company has a diagnostic manufacturing facility at Norwest Business Park, Sydney, Australia. HA TECH has also recently invested in Bangladesh to set up Bulk API (Active Pharmaceutical Ingredient) and diagnostic raw materials production facilities. Key Projects and Product Pipeline: - The Company has launched a multi-gene target SARS-CoV-2 RT-PCR kit in October 2020 that is one of the fastest available globally. The Kit received TGA approval in December 2020 and is available for sale in Australia and overseas. The company is also developing a range of other diagnostic kits concurrently such as a multiplex kit for testing SARS-CoV-2, Influenza and RSV and a kit for differentiating Dengue, Chikungunya and Zika virus. Development has also begun for a rapid SARS-CoV-2 point of care test and an environmental surface SARS-CoV-2 test kit. - The development and manufacturing of Biotherapeutic drugs; and Active Pharmaceuticals Ingredients (APIs) for Cardiovascular, Antidiabetic, Anti-Ulcerant and Oncology applications. - The development & commercialization of novel technologies based on smart materials such as polymer nanoparticles, polymer hydrogel and hydrogel me read more